These findings identified CDK4 as a main coordinator of metabolic and survival responses in TNBC cells [90], further suggesting that the metabolic vulnerabilities acquired by TNBC cells upon CDK4 inhibition could be exploited as potential therapeutic targets in order to overcome resistance and impair tumour survival. The gene discussed is CDK4; the disease is neoplasm.